Premium
The Tuberculosis Drug Streptomycin as a Potential Cancer Therapeutic: Inhibition of miR‐21 Function by Directly Targeting Its Precursor
Author(s) -
Bose Debojit,
Jayaraj Gopal,
Suryawanshi Hemant,
Agarwala Prachi,
Pore Subrata Kumar,
Banerjee Rajkumar,
Maiti Souvik
Publication year - 2012
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201106455
Subject(s) - dicer , streptomycin , microrna , drosha , function (biology) , drug , tuberculosis , gene silencing , biology , small interfering rna , rna interference , gene , chemistry , cancer research , rna , pharmacology , microbiology and biotechnology , biochemistry , medicine , antibiotics , pathology
No dice : MicroRNAs (miRNAs) fine‐tune gene expression, deregulation of which has been causally associated with a number of debilitating conditions. Streptomycin, a well‐known aminoglycoside drug, binds to RNA secondary structures and is shown to inhibit miR‐21 function by direct binding to its precursor, thus presumably interfering with the processing by the Dicer enzyme (see scheme).